Evaluating the association between genetically proxied ACE inhibition and dementias.
ACE
Alzheimer's
Mendelian randomization
angiotensin-converting enzyme
angiotensin-converting enzyme inhibitor
dementia
frontotemporal
genomics
neurodegeneration
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
03
03
2023
received:
12
10
2022
accepted:
08
03
2023
medline:
15
9
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
Angiotensin-converting enzyme (ACE) has been implicated in the metabolism of amyloid beta; however, the causal effect of ACE inhibition on risk of Alzheimer's disease (AD) dementia and other common dementias is largely unknown. We examined the causal association of genetically proxied ACE inhibition with four types of dementias using a two-sample Mendelian randomization (MR) approach. Genetically proxied ACE inhibition was associated with increased risk of AD dementia (odds ratio per one standard deviation reduction in serum ACE [95% confidence interval]; 1.07 [1.04-1.10], P = 5 × 10 This comprehensive MR study provided genetic evidence for an association between ACE inhibition and the risk for AD and frontotemporal dementias. These results should encourage further studies of the neurocognitive effects of ACE inhibition. This study evaluated genetically proxied angiotensin-converting enzyme (ACE) inhibition association with dementias. The results suggest an association between ACE inhibition and Alzheimer's disease. The results suggest an association between ACE inhibition and frontotemporal dementia. Those associations can be interpreted as potentially causal.
Substances chimiques
Amyloid beta-Peptides
0
Angiotensins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3894-3901Informations de copyright
© 2023 the Alzheimer's Association.
Références
Tisher A, Salardini A. A comprehensive update on treatment of dementia. Semin Neurol. 2019;39:167-178.
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021;397:1577-1590.
Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7:33.
Ackley SF, Zimmerman SC, Brenowitz WD, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372:n156.
Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18:794-799.
Dourlen P, Kilinc D, Malmanche N, Chapuis J, Lambert JC. The new genetic landscape of Alzheimer's disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol. 2019;138:221-236.
Bellenguez C, Kucukali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022;54:412-436.
Le D, Brown L, Malik K, Murakami S. Two opposing functions of angiotensin-converting enzyme (ACE) that links hypertension, dementia, and aging. Int J Mol Sci. 2021:22.
Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280:37644-37650.
Liu S, Ando F, Fujita Y, et al. A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice. J Biol Chem. 2019;294:9760-9770.
Qiu WQ, Mwamburi M, Besser LM, et al. Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. J Alzheimers Dis. 2013;37:421-428.
Soto ME, van Kan GA, Nourhashemi F, et al. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Reseau sur la Maladie d'Alzheimer Francais cohort. J Am Geriatr Soc. 2013;61:1482-1488.
Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.
Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021;375:n2233.
Pigeyre M, Sjaarda J, Chong M, et al. ACE and Type 2 diabetes risk: a Mendelian Randomization Study. Diabetes Care. 2020;43:835-842.
Gerstein HC, Pare G, McQueen MJ, Lee SF, Hess S. Investigators OT. Validation of the ORIGIN cardiovascular biomarker panel and the value of adding Troponin I in dysglycemic people. J Clin Endocrinol Metab. 2017;102:2251-2257.
Escott-Price V, Hardy J. Genome-wide association studies for Alzheimer's disease: bigger is not always better. Brain Commun. 2022;4:fcac125.
Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51:414-430.
Ferrari R, Hernandez DG, Nalls MA, et al. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol. 2014;13:686-699.
Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456-2477.
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006-1014.
Reus LM, Jansen IE, Mol MO, et al. Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. Transl Psychiatry. 2021;11:451.
van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62:1091-1111.
Chia R, Sabir MS, Bandres-Ciga S, et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021;53:294-303.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88-100.
Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22:1689-1707. quiz 837.
Kurki MI, Karjalainen J, Palta P, et al. FinnGen: unique genetic insights from combining isolated population and national health register data. medRxiv. 2022:2022.03.03.22271360.
Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7.
Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res. 2019;4:186.
Wingo AP, Liu Y, Gerasimov ES, et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis. Nat Genet. 2021;53:143-146.
Xin XY, Lai ZH, Ding KQ, Zeng LL, Ma JF. Angiotensin-converting enzyme polymorphisms AND Alzheimer's disease susceptibility: an updated meta-analysis. PLoS One. 2021;16:e0260498.
Miners JS, van Helmond Z, Raiker M, Love S, Kehoe PG. ACE variants and association with brain Abeta levels in Alzheimer's disease. Am J Transl Res. 2010;3:73-80.
Kehoe PG, Katzov H, Andreasen N, et al. Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease. Hum Genet. 2004;114:478-483.
Kauwe JS, Bailey MH, Ridge PG, et al. Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet. 2014;10:e1004758.
Rocha NP, Toledo A, Corgosinho LTS, et al. Cerebrospinal fluid levels of angiotensin-converting enzyme are associated with amyloid-beta42 burden in Alzheimer's disease. J Alzheimers Dis. 2018;64:1085-1090.
Xin XY, Zhao QH, Huang Q, et al. Genetic profiles of familial late-onset Alzheimer's disease in China: the Shanghai FLOAD study. Genes & Diseases. 2021.
Ryan DK, Karhunen V, Su B, et al. Genetic evidence for protective effects of angiotensin-converting enzyme against Alzheimer disease but not other neurodegenerative diseases in European populations. Neurol Genet. 2022;8:e200014.
Ou YN, Yang YX, Deng YT, et al. Identification of novel drug targets for Alzheimer's disease by integrating genetics and proteomes from brain and blood. Mol Psychiatry. 2021;26:6065-6073.
Gao Y, O'Caoimh R, Healy L, et al. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open. 2013;3.
Cuddy LK, Prokopenko D, Cunningham EP, et al. Abeta-accelerated neurodegeneration caused by Alzheimer's-associated ACE variant R1279Q is rescued by angiotensin system inhibition in mice. Sci Transl Med. 2020:12.
Miners S, Ashby E, Baig S, et al. Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res. 2009;1:163-177.
Jochemsen HM, Teunissen CE, Ashby EL, et al. The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. Alzheimers Res Ther. 2014;6:27.
Fazal K, Perera G, Khondoker M, Howard R, Stewart R. Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer's disease. BJPsych Open. 2017;3:158-164.
Zou K, Yamaguchi H, Akatsu H, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci. 2007;27:8628-8635.
Ouk M, Wu CY, Rabin JS, et al. Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Neurobiol Aging. 2021;100:22-31.
Koronyo-Hamaoui M, Sheyn J, Hayden EY, et al. Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease. Brain. 2020;143:336-358.
Asraf K, Torika N, Danon A. Fleisher-Berkovich S. Involvement of the Bradykinin B1 receptor in microglial activation. In Vitro and In Vivo Studies Front Endocrinol (Lausanne). 2017;8:82.
Singh PK, Chen ZL, Ghosh D, Strickland S, Norris EH. Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer's patients. Neurobiol Dis. 2020;139:104833.
Scotti L, Bassi L, Soranna D, et al. Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia: a meta-analysis. Pharmacol Res. 2021;166:105515.
Hajjar I, Okafor M, McDaniel D, et al. Effects of Candesartan vs lisinopril on neurocognitive function in older adults with executive mild cognitive impairment: a randomized clinical trial. JAMA Netw Open. 2020;3:e2012252.
Marcum ZA, Gabriel N, Bress AP, Hernandez I. Association of new use of antihypertensives that stimulate vs inhibit Type 2 and 4 angiotensin II receptors with dementia among medicare beneficiaries. JAMA Netw Open. 2023;6:e2249370.
Pressman PS, Miller BL. Diagnosis and management of behavioral variant frontotemporal dementia. Biol Psychiatry. 2014;75:574-581.